Company profile
CORBUS PHARMACEUTICALS HOLDINGS, INC.
NASDAQ:CRBPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LENABASUM | phase3 | — | 6 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07310901 | phase1 | completed | 2025-12-04 | 2026-08-03 | Corbus Pharmaceuticals Inc. | A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity |
| NCT06265727 | phase1_2 | recruiting | 2024-04-01 | 2027-01-16 | Corbus Pharmaceuticals Inc. | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors |
| NCT07768189 | phase3 | recruiting | 2026-09-29 | 2027-12-01 | Corbus Pharmaceuticals Inc. | A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma |
| NCT06603844 | phase1_2 | recruiting | 2024-12-04 | 2026-11-01 | Corbus Pharmaceuticals Inc. | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. |
| NCT02465437 | phase2 | terminated | 2015-08-01 | 2016-10-01 | Corbus Pharmaceuticals Inc. | Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis |
FDA applications (0)
No records yet.